Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer/Algeta’s Xofigo Brings New Mechanism To Prostate Cancer Field

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approved the first alpha particle-emitting radioactive therapeutic agent, Bayer/Algeta’s Xofigo (radium Ra 223 dichloride), for prostate cancer patients with symptomatic bone metastases, three months ahead of the expected PDUFA date.

You may also be interested in...



Bayer Execs Silent On Plans To Divest Material Sciences

The diversified German big pharma highlighted the sales growth of its five recently launched drugs in the first quarter, but declined to fuel M&A speculation surrounding its non-life sciences division.

Bayer Execs Silent On Plans To Divest Material Sciences

The diversified German big pharma highlighted the sales growth of its five recently launched drugs in the first quarter, but declined to fuel M&A speculation surrounding its non-life sciences division.

Singapore First In Asia To Offer Bayer’s Novel Radiation Therapy For Advanced Prostate Cancer With Bone Metastases

Bayer has launched Xofigo (Ra 223) in Singapore, making it the first Asian nation to offer the treatment and cementing the wealthy city state’s claims as a cutting edge cancer treatment hub.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075681

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel